Latest Health stories from Life.
This editorial examines the collaboration between the U.S. government and Gavi, the Vaccine Alliance, focusing on their efforts to enhance immunization access in lower-income countries.
A suspected hantavirus outbreak on a cruise ship has resulted in three fatalities and additional illnesses. Here’s what we know about this rodent-borne disease.
Two pharmaceutical companies are appealing to the U.S. Supreme Court to reinstate mail-order access to mifepristone, following a suspension by an appeals court.
In a significant legal development, a federal court has blocked the mailing of mifepristone, a medication used in abortion care, as health news continues to evolve.
Latus Bio has successfully raised $42 million to advance its gene therapy aimed at treating Huntington's disease, with plans to seek FDA approval for a clinical trial.
The concept of 'blue zones' has evolved significantly, raising questions about its authenticity and origins, as discussed by Shelley Wood and Eric Topol.
China's new supply chain regulations may pose significant challenges for Western biopharma companies as the country asserts its role as a competitor in drug innovation.
A recent federal appeals court ruling has determined that mifepristone, a medication used in the majority of abortions in the U.S., can now only be distributed in person at clinics.
A recent opinion piece highlights the difficulties faced by advocates in addressing misinformation and promoting diversity in medical education.
A recent discussion highlights medical students' views on the integration of preventive care education in their curriculum, revealing concerns about coherence in their training.
The pharmaceutical sector sees significant movement with new appointments and changes. Ailux has appointed Maria Belvisi as chief scientific officer among other updates.
In a significant development for Alzheimer's care, Axsome has received FDA approval for a treatment aimed at alleviating agitation associated with the disease.
The FDA's recent proposal to exclude active ingredients in obesity drugs from the compounding list has sparked significant concerns within the industry, coinciding with AstraZeneca's challenges in drug development.
Recent reports indicate that PFAS chemicals remain present in certain infant formulas, raising ongoing health concerns as Casey Means steps down as surgeon general nominee.
This editorial discusses the Temporary Protected Status (TPS) program, recent changes made by the Trump administration, and the potential health care implications for affected individuals.
Recent updates to the Medicare Advantage program introduce new consumer protections while also rolling back some existing safeguards, according to the finalized policies by CMS.
A recent FDA review has confirmed the overall safety of 16 baby formula brands, yet low-level PFAS findings have raised concerns among parents. Experts weigh in on the implications.
Julia Vintarello is embarking on a new biotech venture aimed at addressing the commercial and regulatory hurdles in the production of customized medicines.
The focus on fertility in America has shifted from concerns about overpopulation to anxieties about declining birth rates, raising questions about societal values.
While psychedelics show great promise as treatments, their development raises complex scientific and political issues that may overlook people of color.